Kineta®, Inc., founded in 2007 by Drs. Charles Magness and Shawn Iadonato, is a biotechnology company focused on the development of new, targeted immune modulating drugs. Our progressive business model is aimed at accelerating advancement of novel medicines to benefit patients and investors more quickly than traditional models.
We develop data-supported, innovative therapies to a point where larger companies can carry them through late stage clinical trials. With less than 45 employees we are developing five drug and vaccine programs with a focus on autoimmune diseases, antivirals and chronic pain. Our lead drug, dalazatide (formerly ShK-186) is in the clinic. All of Kineta’s drugs have unique mechanisms of action and are aimed at addressing unmet medical needs. We foster innovation through academic collaborations and grow by publishing ground-breaking science. Our corporate partners enable us to do complete preclinical drug development.
In March of 2014 Seattle Business Magazine named Kineta the winner in the field of biopharmaceutical achievement for its innovative approach to drug development and investor-friendly business plan.